PDF(Pubmed)
Abstract：
BACKGROUND: Grapiprant is a novel anti-inflammatory drug approved for the treatment of pain associated with osteoarthritis in dogs.
OBJECTIVE: Compare the efficacy of grapiprant vs meloxicam for the management of postoperative joint pain in dogs.
METHODS: Forty-eight dogs presented with cranial cruciate ligament disease and treated by tibial plateau leveling osteotomy (TPLO) between May 2020 and May 2022.
METHODS: In this randomized, double blinded, prospective clinical trial, client-owned dogs with naturally occurring unilateral cruciate ligament rupture were enrolled on the day of surgery. The day after surgery, all animals received a subcutaneous injection of 0.2 mg/kg of meloxicam and were randomly assigned to receive either oral grapiprant (2 mg/kg) or meloxicam (0.1 mg/kg), once a day for 14 days, in a blinded manner. The primary endpoint of the study was the pain severity (PSS) and interference (PIS) scores, assessed by the Canine Brief Pain Inventory (CBPI) at day 3, 7, 10 and 15 after the surgery.
RESULTS: Three days after surgery, grapiprant treated dogs had lower PSS compared to meloxicam treated dogs with a mean ± SD of 2.76 ± 0.18 vs 3.25 ± 0.23, respectively (difference of -0.49 [95% CI -0.94 to -0.04], P = .032). Pain Interference Score was also lower in grapiprant group at day 3 (4.11 ± 0.18 vs 4.69 ± 0.16 in meloxicam group [difference of -0.58 {95% CI -1.03 to -0.13}, P = .013]) and at day 10 (2.23 ± 0.13 vs 2.72 ± 0.28 [difference of -0.49 {95% CI -0.92 to -0.01}, P = .049]).
CONCLUSIONS: Our study supports the use of grapiprant as an alternative analgesic to meloxicam for management of postoperative joint pain in dogs.
OBJECTIVE: Compare the efficacy of grapiprant vs meloxicam for the management of postoperative joint pain in dogs.
METHODS: Forty-eight dogs presented with cranial cruciate ligament disease and treated by tibial plateau leveling osteotomy (TPLO) between May 2020 and May 2022.
METHODS: In this randomized, double blinded, prospective clinical trial, client-owned dogs with naturally occurring unilateral cruciate ligament rupture were enrolled on the day of surgery. The day after surgery, all animals received a subcutaneous injection of 0.2 mg/kg of meloxicam and were randomly assigned to receive either oral grapiprant (2 mg/kg) or meloxicam (0.1 mg/kg), once a day for 14 days, in a blinded manner. The primary endpoint of the study was the pain severity (PSS) and interference (PIS) scores, assessed by the Canine Brief Pain Inventory (CBPI) at day 3, 7, 10 and 15 after the surgery.
RESULTS: Three days after surgery, grapiprant treated dogs had lower PSS compared to meloxicam treated dogs with a mean ± SD of 2.76 ± 0.18 vs 3.25 ± 0.23, respectively (difference of -0.49 [95% CI -0.94 to -0.04], P = .032). Pain Interference Score was also lower in grapiprant group at day 3 (4.11 ± 0.18 vs 4.69 ± 0.16 in meloxicam group [difference of -0.58 {95% CI -1.03 to -0.13}, P = .013]) and at day 10 (2.23 ± 0.13 vs 2.72 ± 0.28 [difference of -0.49 {95% CI -0.92 to -0.01}, P = .049]).
CONCLUSIONS: Our study supports the use of grapiprant as an alternative analgesic to meloxicam for management of postoperative joint pain in dogs.
摘要：
背景：Grapiprant是一种新型的抗炎药，被批准用于治疗与狗的骨关节炎相关的疼痛。
目的：比较格立普兰与美洛昔康治疗犬术后关节疼痛的疗效。
方法：在2020年5月至2022年5月期间，有48只狗患有颅交叉韧带疾病，并通过胫骨平台平整截骨术（TPLO）进行治疗。
方法：在本随机分组中，双盲,前瞻性临床试验，患者在手术当天纳入了有自然发生的单侧交叉韧带破裂的患者饲养犬.手术后的第二天,所有动物均接受皮下注射0.2mg/kg美洛昔康，并随机分配接受口服格立普兰（2mg/kg）或美洛昔康（0.1mg/kg），每天一次，持续14天，以盲目的方式。研究的主要终点是疼痛严重程度（PSS）和干扰（PIS）评分，在手术后第3、7、10和15天通过犬简短疼痛量表（CBPI）进行评估。
结果：手术后三天，与美洛昔康治疗的狗相比，用grapiprant治疗的狗的PSS较低，平均±SD分别为2.76±0.18和3.25±0.23（差异为-0.49[95％CI-0.94至-0.04]，P=.032）。在第3天，grapiprant组的疼痛干扰评分也较低（4.11±0.18vs美洛昔康组的4.69±0.16[差异为-0.58{95％CI-1.03至-0.13}，P=.013]）和第10天（2.23±0.13vs2.72±0.28[差异为-0.49{95％CI-0.92至-0.01}，P=.049]）。
结论：我们的研究支持使用grapiprant作为美洛昔康的替代镇痛药来治疗狗术后关节疼痛。
目的：比较格立普兰与美洛昔康治疗犬术后关节疼痛的疗效。
方法：在2020年5月至2022年5月期间，有48只狗患有颅交叉韧带疾病，并通过胫骨平台平整截骨术（TPLO）进行治疗。
方法：在本随机分组中，双盲,前瞻性临床试验，患者在手术当天纳入了有自然发生的单侧交叉韧带破裂的患者饲养犬.手术后的第二天,所有动物均接受皮下注射0.2mg/kg美洛昔康，并随机分配接受口服格立普兰（2mg/kg）或美洛昔康（0.1mg/kg），每天一次，持续14天，以盲目的方式。研究的主要终点是疼痛严重程度（PSS）和干扰（PIS）评分，在手术后第3、7、10和15天通过犬简短疼痛量表（CBPI）进行评估。
结果：手术后三天，与美洛昔康治疗的狗相比，用grapiprant治疗的狗的PSS较低，平均±SD分别为2.76±0.18和3.25±0.23（差异为-0.49[95％CI-0.94至-0.04]，P=.032）。在第3天，grapiprant组的疼痛干扰评分也较低（4.11±0.18vs美洛昔康组的4.69±0.16[差异为-0.58{95％CI-1.03至-0.13}，P=.013]）和第10天（2.23±0.13vs2.72±0.28[差异为-0.49{95％CI-0.92至-0.01}，P=.049]）。
结论：我们的研究支持使用grapiprant作为美洛昔康的替代镇痛药来治疗狗术后关节疼痛。
